All the news Showing 10 of 64 articles from: Ns5A inhibitorsGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Sofosbuvir/velpatasvir + GS-9857 for 8 weeks cures hepatitis C for most people with genotype 1 or 3 Liz Highleyman / 16 November 2015 An 8-week triple combination of Gilead Sciences' sofosbuvir, velpatasvir and GS-9857 showed a high sustained response rate in a phase 2 study of people with difficult-to-treat hepatitis C virus (HCV), including treatment-experienced people ... Grazoprevir/elbasvir shows high hepatitis C cure rate for people who inject drugs Liz Highleyman / 16 November 2015 Merck's grazoprevir/elbasvir coformulation cured hepatitis C infection in 92% of injecting drug users receiving opioid substitution therapy in the C-EDGE CO-STAR study, according to a presentation on Sunday at the 2015 AASLD ... New HCV NS5A inhibitor EDP-239 looks good in early studies, more evidence supports early hepatitis C treatment Keith Alcorn / 07 October 2015 A new hepatitis C virus (HCV) NS5A inhibitor being developed by Enanta – EDP-239 – was well-tolerated and demonstrated promising antiviral activity against genotype 1 HCV in a single-dose monotherapy study presented at ... Sofosbuvir plus daclatasvir for 12 weeks cures HCV for most people with HIV/HCV co-infection Liz Highleyman / 04 June 2015 Nearly all trial participants with HIV and hepatitis C virus (HCV) co-infection, who were treated for 12 weeks with an interferon- and ribavirin-free regimen of sofosbuvir (Sovaldi) and daclatasvir (Daklinza), achieved ... Sofosbuvir-based therapy effective for hepatitis C patients with decompensated cirrhosis Liz Highleyman / 06 May 2015 Interferon-free regimens containing sofosbuvir (Sovaldi) plus simeprevir (Olysio) cured about three-quarters of people with genotype 1 chronic hepatitis C with advanced cirrhosis and MELD scores >10 in the real-world HCV-TARGET study, researchers reported ... Grazoprevir / elbasvir highly effective in previously untreated hepatitis C Keith Alcorn / 24 April 2015 A 12-week course of the combination of grazoprevir and elbasvir cured 95% of previously untreated people with gentoypes 1, 4 or 6 hepatitis C infection, according to results of the C-EDGE trial, ... AbbVie next-generation hepatitis C drugs look promising in early studies Liz Highleyman / 03 March 2015 AbbVie's investigational HCV protease inhibitor ABT-493 and NS5A inhibitor ABT-530 demonstrated good antiviral activity in people with genotype 1 chronic hepatitis C in a three-day monotherapy study, as well as potent and ... Sofosbuvir/ledipasvir cures most previously treated hepatitis C patients with cirrhosis Liz Highleyman / 07 January 2015 Difficult-to-treat hepatitis C patients with liver cirrhosis who were not cured with a prior course of first-generation HCV protease inhibitors had a sustained response rate of 96-97% when re-treated with sofosbuvir/ledipasvir with ribavirin ... Daclatasvir + sofosbuvir demonstrates good cure rate for genotype 3 hepatitis C Liz Highleyman / 04 December 2014 An all-oral combination of daclatasvir (Daklinza) plus sofosbuvir (Sovaldi), taken for 12 weeks, produced sustained virological response rates of 90% for previously untreated patients and 86% for prior non-responders with hepatitis C virus ... Sofosbuvir + GS-5816 for 12 weeks shows high HCV cure rates, but 8 weeks is less effective for some patients Liz Highleyman / 02 December 2014 A 12-week oral combination of sofosbuvir plus the experimental NS5A inhibitor GS-5816 demonstrated high sustained virological response rates for people with difficult-to-treat HCV genotype 3 and other genotypes, according to phase 2 study ... ← Prev12345...7Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive